We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Gyros Expands Commercial Reach in Asia

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

S.E. Kim, president and CEO at DI Biotech, the sole distributor of Gyros products in South Korea, commented: “We are extremely pleased that Binex has become the first South Korean customer to adopt this exciting new platform. Our goal at DIBiotech is to ensure that our customers have access to the latest ground-breaking technologies. We firmly believe that the Gyros platform, will not only increase productivity, but also boost the competitiveness of South Korea’s pharma and biotech companies as well as our CROs and CMOs.”

The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, to boost time-critical workflows and help meet regulatory demands. The platform comprises a Gyrolab workstation, control and evaluation software and the unique microfluidic CDs in which immunoassay steps are integrated and run at nanoliter scale.

Erik Walldén, CEO at Gyros, continued, “We have been actively expanding our distributor network throughout the Asia-Pacific region and see this as a significant step on the way to establishing a global presence for our immunoassay platform.”